Franziska K. Lorbeer

Research Institute of Molecular Pathology — Austria

Biochemistry, Genetics and Molecular Biology · Life Sciences

9h-index1.4kcitations48works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related molecular mechanisms research(14), Glioma Diagnosis and Treatment(13), RNA Research and Splicing(12), RNA modifications and cancer(12), Telomeres, Telomerase, and Senescence(9)

Publications48 total

A foundational model for joint sequence-function multi-species modeling at scale for long-range genomic prediction
2025· 3 citedOpen Access
Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2025Open Access
Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2025Open Access
Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2025Open Access
Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2025Open Access
Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2025Open Access
Distinct senescence mechanisms restrain progression of dysplastic nevi
PNAS Nexus·2024· 5 citedOpen Access
Distinct senescence mechanisms restrain progression of dysplastic nevi
2023· 3 citedOpen Access
Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2023Open Access
Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2023Open Access
Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2023Open Access
Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2023Open Access
Data from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2023Open Access
Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2023Open Access
Data from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2023Open Access
Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2023Open Access
Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2023Open Access
Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2023Open Access
Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2023Open Access
Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Sied Kebir(18), Vivien Ullrich(18), Pia Berger(18), Celia Dobersalske(18), Sarah Langer(18), Laurèl Rauschenbach(18), Daniel Trageser(18), Andreas Till(18), Anja Wieland(18), Timo Wilhelm-Buchstab(18), Ashar Ahmad(18), Holger Fröhlich(18), Igor Cima(18), Shruthi Prasad(18), Johann Matschke(18), Verena Jendrossek(18), Marc Remke(18), Barbara M. Grüner(18), Alexander Roesch(18), Jens T. Siveke(18)